Home Cart Sign in  
Chemical Structure| 312636-16-1 Chemical Structure| 312636-16-1

Structure of SKI II
CAS No.: 312636-16-1

Chemical Structure| 312636-16-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SKI II is an inhibitor of non ATP-competitive sphingosine kinase (SphK) with IC50 of 0.5 μM.

Synonyms: Sphingosine Kinase Inhibitor 2; SphK-I2; SKI II. Sphingosine kinase inhibitor II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SKI II

CAS No. :312636-16-1
Formula : C15H11ClN2OS
M.W : 302.78
SMILES Code : OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1
Synonyms :
Sphingosine Kinase Inhibitor 2; SphK-I2; SKI II. Sphingosine kinase inhibitor II
MDL No. :MFCD00733553
InChI Key :ZFGXZJKLOFCECI-UHFFFAOYSA-N
Pubchem ID :753704

Safety of SKI II

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U3054MG cells 2.66 µM 5 days Decreased invasion of glioblastoma cell spheroids PMC10433583
1080 GSCs 2.66 µM 4 weeks Impaired the self-renewal capacity of temozolomide-resistant GSCs PMC10433583
A2780 ovarian cancer cells 5 μM 48 hours SKI-II synergized with curcumin to inhibit A2780 cell proliferation PMC7659178
SKOV3 ovarian cancer cells 5 μM 48 hours SKI-II synergized with curcumin to inhibit SKOV3 cell proliferation PMC7659178
HK-2 cells 5 μM 24 hours Inhibition of SK1 activity completely abolished the protective effect of hiPSC-MSCs-EVs on H/R-injured HK-2 cells PMC5870585
HeLa 10 μM 24 hours SKI II treatment significantly increased the levels of dhSM and dhCDH in HeLa cells, indicating inhibition of Des1 activity. PMC4109765
T98G 10 μM 24 hours SKI II treatment significantly increased the levels of dhSM and dhCDH in T98G cells, indicating inhibition of Des1 activity. PMC4109765
PC12 cells 10 µM 24 hours To study the effect of SKI II on PC12 cell viability, results showed that SKI II significantly decreased the viability of PC12 cells. PMC3962740
CaOV3 ovarian cancer cells 5 μM 24-48 hours SKI-II significantly enhanced curcumin-induced apoptosis and growth inhibition by facilitating ceramide production, p38 activation and Akt inhibition PMC7659178
HGC 27 10 μM 4 hours SKI II significantly reduced the production of CerC6NBD in HGC 27 cells, indicating inhibition of Des1 activity. PMC4109765
Rat islet cells 10 or 20 μM 48 hours To assess the effect of SKI II on oleate-induced β-cell proliferation, results showed that SKI II inhibited oleate-induced β-cell proliferation. PMC9163557
NCH82 cells 2.66 µM 5 days Synergistically inhibited glioblastoma cell growth and potentiated glioblastoma cell death PMC10433583
Primary human peripheral blood lymphocytes (PBL) 5 μM 6-24 hours Reduced phosphorylation of rpS6 and eIF4E, affecting cellular translational capacity PMC8968423
HT-29 cells 5 μM 72 hours Facilitated ABC294640-induced cytotoxicity against HT-29 cells PMC4559903

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Renal ischemia-reperfusion injury model Subcutaneous injection 50 mg/kg Single dose 15 min before reperfusion SK1 inhibition completely abolished the renal protective effect of hiPSC-MSCs-EVs in a rat I/R injury model PMC5870585
Wistar rats Glucose and lipid emulsion (GLU + CLI) infusion model Oral gavage 50 mg/kg Once daily for 72 hours To assess the effect of SKI II on GLU + CLI-induced β-cell proliferation, results showed a negative correlation between plasma SKI II levels and β-cell proliferation. PMC9163557
C57BL/6 mice AOM-induced colon carcinogenesis model Oral 100 mg/kg Once a week for 3 weeks SKI-II significantly reduced the number of ACF per colon induced by AOM PMC5862304

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.51mL

3.30mL

1.65mL

33.03mL

6.61mL

3.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories